Carbaspirin calcium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Carbaspirin calcium
Accession Number
DB13612
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Carbasalate calcium
  • Carbasalato calcico
  • Carbasalatum calcicum
Categories
UNII
N667F17JP1
CAS number
5749-67-7
Weight
Average: 458.436
Monoisotopic: 458.0638211
Chemical Formula
C19H18CaN2O9
InChI Key
VYMUGTALCSPLDM-UHFFFAOYSA-L
InChI
InChI=1S/2C9H8O4.CH4N2O.Ca/c2*1-6(10)13-8-5-3-2-4-7(8)9(11)12;2-1(3)4;/h2*2-5H,1H3,(H,11,12);(H4,2,3,4);/q;;;+2/p-2
IUPAC Name
calcium urea bis(2-(acetyloxy)benzoate)
SMILES
[Ca++].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Carbaspirin calcium.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Carbaspirin calcium.Approved
AcarboseCarbaspirin calcium may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololCarbaspirin calcium may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolCarbaspirin calcium may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Carbaspirin calcium.Approved
AlbiglutideCarbaspirin calcium may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Carbaspirin calcium.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alendronic acid.Approved
AliskirenCarbaspirin calcium may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Carbaspirin calcium.Experimental
AlogliptinCarbaspirin calcium may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Carbaspirin calcium.Experimental
AlprenololCarbaspirin calcium may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Carbaspirin calcium.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Amcinonide.Approved
AmikacinCarbaspirin calcium may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideCarbaspirin calcium may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Aminosalicylic Acid.Approved
AmiodaroneCarbaspirin calcium may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
Ammonium chlorideThe serum concentration of Carbaspirin calcium can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Carbaspirin calcium.Approved
AncrodCarbaspirin calcium may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Carbaspirin calcium.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Carbaspirin calcium.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Antipyrine.Approved, Investigational
Antithrombin III humanCarbaspirin calcium may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Antrafenine.Approved
ApixabanCarbaspirin calcium may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Carbaspirin calcium.Investigational
ApramycinCarbaspirin calcium may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Carbaspirin calcium.Approved, Investigational
AprotininThe therapeutic efficacy of Carbaspirin calcium can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArbekacinCarbaspirin calcium may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinCarbaspirin calcium may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Carbaspirin calcium.Approved, Investigational
ArotinololCarbaspirin calcium may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineCarbaspirin calcium may decrease the antihypertensive activities of Asenapine.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Atamestane.Investigational
AtenololCarbaspirin calcium may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Carbaspirin calcium.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Carbaspirin calcium.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Carbaspirin calcium.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Carbaspirin calcium.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Batroxobin.Experimental
BecaplerminCarbaspirin calcium may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCarbaspirin calcium may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinCarbaspirin calcium may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Bemiparin.Approved, Investigational
BenazeprilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Carbaspirin calcium.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Carbaspirin calcium.Approved
BenorilateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Carbaspirin calcium.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Carbaspirin calcium.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Benzydamine.Approved
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Carbaspirin calcium.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Betamethasone.Approved, Vet Approved
BetaxololCarbaspirin calcium may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Carbaspirin calcium.Approved, Investigational
BevantololCarbaspirin calcium may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Carbaspirin calcium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
BisoprololCarbaspirin calcium may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinCarbaspirin calcium may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololCarbaspirin calcium may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Bromfenac.Approved
BromocriptineCarbaspirin calcium may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Carbaspirin calcium.Investigational
BucindololCarbaspirin calcium may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Bufexamac.Approved, Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Carbaspirin calcium.Experimental
BufuralolCarbaspirin calcium may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Carbaspirin calcium.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Carbaspirin calcium.Approved
BupranololCarbaspirin calcium may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Carbaspirin calcium.Investigational
CanagliflozinCarbaspirin calcium may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Carbaspirin calcium.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Carbaspirin calcium.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Carbaspirin calcium.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Carbaspirin calcium.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Caplacizumab.Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Capsaicin.Approved
CaptoprilThe therapeutic efficacy of Captopril can be decreased when used in combination with Carbaspirin calcium.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Carbaspirin calcium.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarbaspirin calcium may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCarbaspirin calcium may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Carbaspirin calcium.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Celecoxib.Approved, Investigational
CeliprololCarbaspirin calcium may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinCarbaspirin calcium may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Carbaspirin calcium.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carbaspirin calcium.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpropamideCarbaspirin calcium may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Carbaspirin calcium.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Carbaspirin calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ciclesonide.Approved, Investigational
CilazaprilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Carbaspirin calcium.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Carbaspirin calcium.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Cimicoxib.Investigational
CinoxacinCarbaspirin calcium may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Cisplatin.Approved
Citric AcidCarbaspirin calcium may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Carbaspirin calcium.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Carbaspirin calcium.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Carbaspirin calcium.Vet Approved
CloranololCarbaspirin calcium may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Carbaspirin calcium.Experimental
ClorindioneCarbaspirin calcium may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Carbaspirin calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Carbaspirin calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Carbaspirin calcium.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Carbaspirin calcium.Experimental
CyclosporineCarbaspirin calcium may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DalteparinCarbaspirin calcium may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCarbaspirin calcium may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinCarbaspirin calcium may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanCarbaspirin calcium may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Carbaspirin calcium.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Carbaspirin calcium.Experimental
DersalazineDersalazine may increase the anticoagulant activities of Carbaspirin calcium.Investigational
DesipramineCarbaspirin calcium may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinCarbaspirin calcium may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexketoprofen.Approved, Investigational
DextranCarbaspirin calcium may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinCarbaspirin calcium may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Carbaspirin calcium.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Diclofenamide.Approved, Investigational
DicoumarolCarbaspirin calcium may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Carbaspirin calcium.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Carbaspirin calcium.Approved
DihydrostreptomycinCarbaspirin calcium may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Carbaspirin calcium.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Carbaspirin calcium.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Carbaspirin calcium.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Carbaspirin calcium.Approved
DiphenadioneCarbaspirin calcium may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Carbaspirin calcium.Approved
DisopyramideCarbaspirin calcium may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dorzolamide.Approved
DrospirenoneCarbaspirin calcium may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Droxicam.Withdrawn
DulaglutideCarbaspirin calcium may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Carbaspirin calcium.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Carbaspirin calcium.Investigational
Edetic AcidCarbaspirin calcium may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCarbaspirin calcium may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinCarbaspirin calcium may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe therapeutic efficacy of Enalapril can be decreased when used in combination with Carbaspirin calcium.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Carbaspirin calcium.Approved
EnoxacinCarbaspirin calcium may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinCarbaspirin calcium may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Carbaspirin calcium.Experimental
EpanololCarbaspirin calcium may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Carbaspirin calcium.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Carbaspirin calcium.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Carbaspirin calcium.Experimental
EplerenoneCarbaspirin calcium may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Carbaspirin calcium.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Carbaspirin calcium.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Carbaspirin calcium.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carbaspirin calcium.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Carbaspirin calcium.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Equilin.Approved
EsatenololCarbaspirin calcium may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololCarbaspirin calcium may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Carbaspirin calcium.Experimental
EthoxzolamideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateCarbaspirin calcium may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Carbaspirin calcium.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Carbaspirin calcium.Investigational, Nutraceutical
ExenatideCarbaspirin calcium may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Carbaspirin calcium.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Carbaspirin calcium.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Carbaspirin calcium.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Carbaspirin calcium.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Carbaspirin calcium.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Carbaspirin calcium.Experimental
Ferulic acidCarbaspirin calcium may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Carbaspirin calcium.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fish oil.Approved, Nutraceutical
FleroxacinCarbaspirin calcium may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Carbaspirin calcium.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fludrocortisone.Approved, Investigational
FluindioneCarbaspirin calcium may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineCarbaspirin calcium may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Carbaspirin calcium.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Carbaspirin calcium.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Carbaspirin calcium.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Carbaspirin calcium.Approved, Nutraceutical, Vet Approved
FondaparinuxCarbaspirin calcium may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumCarbaspirin calcium may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Carbaspirin calcium.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Carbaspirin calcium.Approved
FramycetinCarbaspirin calcium may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Carbaspirin calcium.Approved, Vet Approved
GabexateCarbaspirin calcium may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinCarbaspirin calcium may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Carbaspirin calcium.Approved, Withdrawn
GemifloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCarbaspirin calcium may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinCarbaspirin calcium may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACarbaspirin calcium may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Carbaspirin calcium.Approved, Investigational, Nutraceutical
GinsengThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ginseng.Approved, Investigational, Nutraceutical
GliclazideCarbaspirin calcium may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideCarbaspirin calcium may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCarbaspirin calcium may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideCarbaspirin calcium may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Carbaspirin calcium.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with HE3286.Investigational
Hemoglobin crosfumarilCarbaspirin calcium may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinCarbaspirin calcium may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
HydralazineCarbaspirin calcium may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carbaspirin calcium.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Carbaspirin calcium.Investigational
Hygromycin BCarbaspirin calcium may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Carbaspirin calcium.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Carbaspirin calcium.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Carbaspirin calcium.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Carbaspirin calcium.Approved, Investigational, Nutraceutical
IdraparinuxCarbaspirin calcium may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Carbaspirin calcium.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Carbaspirin calcium.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Carbaspirin calcium.Approved, Investigational
ImidaprilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Carbaspirin calcium.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Carbaspirin calcium.Approved
IndenololCarbaspirin calcium may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Carbaspirin calcium.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Carbaspirin calcium.Withdrawn
Insulin AspartCarbaspirin calcium may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCarbaspirin calcium may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCarbaspirin calcium may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCarbaspirin calcium may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCarbaspirin calcium may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCarbaspirin calcium may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carbaspirin calcium.Approved, Investigational
IsepamicinCarbaspirin calcium may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Carbaspirin calcium.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Istaroxime.Investigational
KanamycinCarbaspirin calcium may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Carbaspirin calcium.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Carbaspirin calcium.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Carbaspirin calcium.Approved
LabetalolCarbaspirin calcium may decrease the antihypertensive activities of Labetalol.Approved
LandiololCarbaspirin calcium may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Carbaspirin calcium.Approved, Investigational
LepirudinCarbaspirin calcium may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanCarbaspirin calcium may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololCarbaspirin calcium may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololCarbaspirin calcium may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Carbaspirin calcium.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Carbaspirin calcium.Experimental
LiraglutideCarbaspirin calcium may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Carbaspirin calcium.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Carbaspirin calcium.Approved
LomefloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Carbaspirin calcium.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Carbaspirin calcium.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Carbaspirin calcium.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Carbaspirin calcium.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Carbaspirin calcium.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with ME-609.Investigational
MecaserminCarbaspirin calcium may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Mefenamic acid.Approved
MelagatranCarbaspirin calcium may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Meloxicam.Approved, Vet Approved
MepindololCarbaspirin calcium may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Carbaspirin calcium.Approved, Investigational, Withdrawn
MetforminCarbaspirin calcium may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Carbaspirin calcium.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carbaspirin calcium.Approved
Methyl salicylateCarbaspirin calcium may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Methylprednisolone.Approved, Vet Approved
MetipranololCarbaspirin calcium may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Carbaspirin calcium.Approved
MetoprololCarbaspirin calcium may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinCarbaspirin calcium may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Carbaspirin calcium.Approved, Experimental
MifepristoneCarbaspirin calcium may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolCarbaspirin calcium may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Carbaspirin calcium.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Carbaspirin calcium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Carbaspirin calcium.Investigational
MoexiprilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Carbaspirin calcium.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Carbaspirin calcium.Approved
MoxifloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Carbaspirin calcium.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Carbaspirin calcium.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Nabumetone.Approved
NadololCarbaspirin calcium may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCarbaspirin calcium may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatCarbaspirin calcium may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Carbaspirin calcium.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Carbaspirin calcium.Investigational
Nalidixic AcidCarbaspirin calcium may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Naproxen.Approved, Vet Approved
NateglinideCarbaspirin calcium may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with NCX 1022.Investigational
NeamineCarbaspirin calcium may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololCarbaspirin calcium may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinCarbaspirin calcium may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinCarbaspirin calcium may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Nepafenac.Approved, Investigational
NetilmicinCarbaspirin calcium may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Carbaspirin calcium.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Carbaspirin calcium.Investigational
NorfloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carbaspirin calcium.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carbaspirin calcium.Approved
OlsalazineCarbaspirin calcium may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Carbaspirin calcium is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe therapeutic efficacy of Omapatrilat can be decreased when used in combination with Carbaspirin calcium.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Carbaspirin calcium.Vet Approved
OtamixabanCarbaspirin calcium may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Oxaprozin.Approved
Oxolinic acidCarbaspirin calcium may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololCarbaspirin calcium may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Carbaspirin calcium.Approved, Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ozagrel.Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Parnaparin.Approved, Investigational
ParomomycinCarbaspirin calcium may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Carbaspirin calcium.Approved, Investigational
PazufloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCarbaspirin calcium may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateCarbaspirin calcium may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineCarbaspirin calcium may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateCarbaspirin calcium may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Carbaspirin calcium.Approved, Investigational
PerindoprilThe therapeutic efficacy of Perindopril can be decreased when used in combination with Carbaspirin calcium.Approved
PhenindioneCarbaspirin calcium may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCarbaspirin calcium may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Carbaspirin calcium.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Phenylbutazone.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Carbaspirin calcium.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carbaspirin calcium.Approved, Investigational
PindololCarbaspirin calcium may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneCarbaspirin calcium may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Pipemidic acidCarbaspirin calcium may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Carbaspirin calcium.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Carbaspirin calcium.Approved, Investigational
Piromidic acidCarbaspirin calcium may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorCarbaspirin calcium may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinCarbaspirin calcium may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Carbaspirin calcium.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pomalidomide.Approved
Potassium CitrateCarbaspirin calcium may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololCarbaspirin calcium may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Carbaspirin calcium.Approved, Investigational
PramlintideCarbaspirin calcium may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Carbaspirin calcium.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Carbaspirin calcium.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Carbaspirin calcium.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Carbaspirin calcium.Approved, Investigational
PropafenoneCarbaspirin calcium may decrease the antihypertensive activities of Propafenone.Approved
PropranololCarbaspirin calcium may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Carbaspirin calcium.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Carbaspirin calcium.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Carbaspirin calcium.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Carbaspirin calcium.Vet Approved
Protein CCarbaspirin calcium may increase the anticoagulant activities of Protein C.Approved
Protein S humanCarbaspirin calcium may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCarbaspirin calcium may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Carbaspirin calcium.Investigational
PuromycinCarbaspirin calcium may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Carbaspirin calcium.Approved
QuinineCarbaspirin calcium may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Carbaspirin calcium.Investigational
RamiprilThe therapeutic efficacy of Ramipril can be decreased when used in combination with Carbaspirin calcium.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Carbaspirin calcium.Investigational
RepaglinideCarbaspirin calcium may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Carbaspirin calcium.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Reteplase.Approved, Investigational
ReviparinCarbaspirin calcium may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinCarbaspirin calcium may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Carbaspirin calcium.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Risedronate.Approved, Investigational
RivaroxabanCarbaspirin calcium may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Rosiglitazone.Approved, Investigational
RosoxacinCarbaspirin calcium may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Carbaspirin calcium.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Carbaspirin calcium.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Carbaspirin calcium.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Carbaspirin calcium.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Carbaspirin calcium.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Carbaspirin calcium.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Saruplase.Experimental
SaxagliptinCarbaspirin calcium may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Selexipag.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Carbaspirin calcium.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Carbaspirin calcium.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Carbaspirin calcium.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carbaspirin calcium.Approved, Vet Approved
SisomicinCarbaspirin calcium may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinCarbaspirin calcium may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateCarbaspirin calcium may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Carbaspirin calcium.Approved
SotalolCarbaspirin calcium may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Carbaspirin calcium.Approved
SpironolactoneCarbaspirin calcium may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Carbaspirin calcium.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Streptokinase.Approved, Investigational
StreptomycinCarbaspirin calcium may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineCarbaspirin calcium may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleCarbaspirin calcium may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Sulfasalazine.Approved
SulfisoxazoleCarbaspirin calcium may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Sulindac.Approved, Investigational
SulodexideCarbaspirin calcium may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Carbaspirin calcium.Investigational
SunitinibCarbaspirin calcium may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Carbaspirin calcium.Experimental
TacrolimusCarbaspirin calcium may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Carbaspirin calcium.Approved
TalinololCarbaspirin calcium may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Carbaspirin calcium.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Carbaspirin calcium.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Carbaspirin calcium.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carbaspirin calcium.Approved, Investigational
TemafloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Carbaspirin calcium.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Carbaspirin calcium.Vet Approved
TerbutalineCarbaspirin calcium may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Carbaspirin calcium.Approved
TertatololCarbaspirin calcium may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Carbaspirin calcium.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Carbaspirin calcium.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Carbaspirin calcium.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololCarbaspirin calcium may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Carbaspirin calcium.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tinzaparin.Approved
TioclomarolCarbaspirin calcium may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Carbaspirin calcium.Approved
TixocortolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tixocortol.Approved, Withdrawn
TobramycinCarbaspirin calcium may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideCarbaspirin calcium may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideCarbaspirin calcium may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Carbaspirin calcium.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Carbaspirin calcium.Approved
TrandolaprilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Carbaspirin calcium.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Carbaspirin calcium.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Carbaspirin calcium.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Carbaspirin calcium.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Carbaspirin calcium.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Triamcinolone.Approved, Vet Approved
TriamtereneCarbaspirin calcium may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Carbaspirin calcium.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Carbaspirin calcium.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Carbaspirin calcium.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Carbaspirin calcium.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Trolamine salicylate.Approved
TrovafloxacinCarbaspirin calcium may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinCarbaspirin calcium may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Carbaspirin calcium.Approved, Investigational
UrokinaseThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Carbaspirin calcium.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Carbaspirin calcium.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Carbaspirin calcium.Approved
VerapamilVerapamil may increase the anticoagulant activities of Carbaspirin calcium.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Carbaspirin calcium.Approved
WarfarinCarbaspirin calcium may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCarbaspirin calcium may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Carbaspirin calcium.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Carbaspirin calcium.Approved, Investigational, Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Carbaspirin calcium.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Carbaspirin calcium.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
20651
ChEMBL
CHEMBL3833325
Wikipedia
Carbasalate_calcium
ATC Codes
B01AC08 — Carbasalate calciumN02BA15 — Carbasalate calcium

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentIntracerebral Hemorrhage / Nonvalvular Atrial Fibrillation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00848 mg/mLALOGPS
logP3.17ALOGPS
logP1.24ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)-7.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area66.43 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity55.28 m3·mol-1ChemAxon
Polarizability16.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylsalicylic acids
Alternative Parents
Phenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Ureas / Carboxylic acid salts / Carboxylic acid esters / Organic calcium salts / Carboxylic acids
show 5 more
Substituents
Acylsalicylic acid / Phenol ester / Benzoic acid / Phenoxy compound / Benzoyl / Dicarboxylic acid or derivatives / Carboxylic acid ester / Carboxylic acid salt / Urea / Carbonic acid derivative
show 13 more
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:45 / Updated on June 02, 2018 08:52